Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[cfDNA sequencing reveals response heterogeneity to first-line camrelizumab plus chemotherapy in esophageal squamous cell carcinoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology] - 23 Jun 2026

Zhang X L, Wang H, Fan W X, Song G H, Guo Z D, Du Y Y, Zhang Y X, Su F, Yang B, Liu M, Gao Y J, Hu W Q, Zhao J

Abstract excerpt

Objective: To analyze the heterogeneity of response to first-line camrelizumab combined with chemotherapy in patients with esophageal squamous cell carcinoma (ESCC) by pretreatment circulating cell-free DNA (cfDNA) sequencing. Methods: A total of 30 patients with human epidermal growth factor receptor 2-negative locally advanced or advanced ESCC who received first-line camrelizumab combined with chemotherapy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cell-Free Nucleic Acids

Share to Esophageal Neoplasms

Share to Esophageal Squamous Cell Carcinoma

Share to Follow-Up Studies

Share to Progression-Free Survival

Source

Identifiers

PMID: 42331551
DOI: 10.3760/cma.j.cn112152-20250928-00489

Genes

ITPR1
TYW1B
KLF14
NKTR
PRRC2B
MAGI2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[cfDNA sequencing reveals response heterogeneity to first-line camrelizumab plus chemotherapy in esophageal squamous cell carcinoma].PMID 42331551Read ↗

Characteristics and response to next-generation sequencing-guided therapy in locally advanced or metastatic esophageal cancer.Semantic proximity Read ↗

Genome-wide and panel-based cell-free DNA characterization of patients with resectable esophageal adenocarcinoma.Semantic proximity Read ↗

Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy.Semantic proximity Read ↗

Multiregion sequencing reveals the genetic correlation of esophageal squamous cell carcinoma and matched cell-free DNASemantic proximity Read ↗

An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.Semantic proximity Read ↗

An update of Clinical value of circulating tumor DNA in esophageal cancer： a systematic review and meta- analysisSemantic proximity Read ↗

<i>cfTrack</i>: Exome-wide mutation analysis of cell-free DNA to simultaneously monitor the full spectrum of cancer treatment outcomes: MRD, recurrence, and evolutionSemantic proximity Read ↗

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR InhibitorSemantic proximity Read ↗

Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancerSemantic proximity Read ↗

Detection of somatic mutations in circulating cell-free DNA from patients with esophageal squamous cell carcinomaSemantic proximity Read ↗

Next Generation Sequencing of Amplified DNA of Circulating Tumor Cells in Resectable Non-Small Cell Lung Cancer: A Comparative Analysis with Primary Cancer Tissue and Cell-Free DNASemantic proximity Read ↗

[Dynamically monitoring circulating tumor DNA as a biomarker for immunotherapy in advanced esophageal squamous cell carcinoma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.